Evidence map›Paper›PMID 41188653›Full record

ArticleJournal of gastroenterology2026

Development of novel serum peptide biomarkers for screening pancreatic cancer.

Nobuhiko Hayashi, Terumi Takahara, Ichiro Yasuda, Hiroki Kawanaka, Banri Ogino, Jun Sakamoto, Toshiki Entani, Kosuke Takahashi, Toyomi Kozawa, Minaki Hamada and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nobuhiko HayashiThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Terumi TakaharaThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Ichiro YasudaThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. yasudaic@med.u-toyama.ac.jp.ORCID 0000-0002-6888-0310
Hiroki KawanakaThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Banri OginoThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Jun SakamotoThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Toshiki EntaniThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Kosuke TakahashiThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Toyomi KozawaThird Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Minaki HamadaProtosera Inc., Osaka, Japan.
Kyoichi AsadaProtosera Inc., Osaka, Japan.
Hitoshi UchiyamaProtosera Inc., Osaka, Japan.
Hidehisa TachikiProtosera Inc., Osaka, Japan.
Toru WatanabeDepartment of Surgery and Science, University of Toyama, Toyama, Japan.
Tsutomu FujiiDepartment of Surgery and Science, University of Toyama, Toyama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic cancer (PC) has a poor prognosis. To overcome this poor prognosis, early detection is mandatory and the development of highly sensitive biomarkers is required. This study aimed to explore a novel and valuable biomarker based on serum peptidomic analysis for screening patients with PC, especially in the early stages.

methodsSerum samples were collected from 106 patients with PC between May 2020 and May 2021. Peptidomic profiles were analyzed using BLOTCHIP

resultsSix PC-specific peptides were selected and an RI formula was established. When the RI cutoff value was set at 0.604, the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve were 84.0%, 93.4%, 92.7%, 85.3%, and 0.935, respectively. They were similarly high in the validation cohort, at 89.3%, 81.7%, 83.0%, 88.4%, and 0.935, respectively. Furthermore, the sensitivity was relatively high at 76.5% even in the early stages (stage 0/1A).

conclusionsThis novel RI based on serum peptide analysis is useful for screening patients with PC, even in the early stages.

Indexed as

Biomarkers, TumorEarly Detection of CancerPancreatic NeoplasmsPeptidesAgedCase-Control StudiesFemaleHumansMaleMass SpectrometryMiddle AgedPredictive Value of TestsROC CurveSensitivity and SpecificityBiomarkers, TumorPeptidesBiomarkerEarly detectionPancreatic cancerPeptide analysis

Identifiers

PMID41188653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.